Summary & Overview
HCPCS L8607: Injectable Bulking Agent for Vocal Cord Medialization, 0.1 ml
HCPCS Level II code L8607 represents an injectable bulking agent for vocal cord medialization, supplied in 0.1 ml units and inclusive of shipping and necessary supplies. The code captures a device-based injectable used to improve glottic closure in patients with vocal fold insufficiency or paresis. Nationally, device and implant codes like L8607 matter for consistent billing of procedural supplies, accuracy in device tracking, and clarity on site-of-service reimbursement.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for vocal cord medialization, the product and service type tied to the code, and what to expect in payer coverage discussions. The publication outlines common modifiers used with device and supply lines, typical sites of service (ambulatory surgical center, hospital outpatient department, occasionally office-based laryngology), and notes where input data is not available such as associated taxonomies or ICD-10 pairings.
This content equips billing managers, coding professionals, and practice administrators with a clear description of L8607, how it maps to the clinical service of vocal fold medialization, and which major payers are relevant for national-level billing considerations.
Billing Code Overview
HCPCS Level II code L8607 describes an injectable bulking agent for vocal cord medialization, packaged in 0.1 ml increments and includes shipping and necessary supplies. The service is the provision of a medical implantable injectable material used to medialize the vocal fold(s) to improve glottic closure.
Service type: Injection of a bulking agent for vocal cord medialization.
Typical site of service: Ambulatory surgical center or hospital outpatient department; may also be used in office-based laryngology procedures depending on clinical setting and provider practice.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65-year-old adult with unilateral vocal fold atrophy and glottic insufficiency causing progressive breathy dysphonia and frequent aspiration of thin liquids. The otolaryngologist evaluates voice quality, performs laryngoscopy confirming incomplete vocal fold closure, and recommends office-based vocal fold medialization using an injectable bulking agent. The procedure uses L8607 (injectable bulking agent for vocal cord medialization, 0.1 ml, includes shipping and necessary supplies) supplied to the clinic. In an ambulatory clinic or procedure room, topical anesthesia and local infiltration are applied; the surgeon injects the bulking agent into the paraglottic space under flexible endoscopic or direct laryngoscopic guidance. The visit includes pre-procedure evaluation, the injection, brief post-procedure observation for airway compromise or adverse reaction, and voice therapy referral. Typical documentation includes indication, informed consent, agent lot number, volume used (multiples of 0.1 ml as applicable), injection site, technique, immediate complications, and follow-up plan.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Surgical procedure performed by the billing physician | Use when the physician who reports the procedure performed the injection. |